Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Rhea-AI Summary

Seismic Therapeutic announced the appointment of Maude Tessier, PhD, as Chief Business Officer. With over 16 years of experience in biotech, Tessier previously held similar roles at Ikena Oncology (NASDAQ: IKNA), where she facilitated a $1B+ partnership with BMS and secured over $260M in capital. Her expertise in business development and strategic initiatives is expected to drive Seismic's long-term growth strategy in immunology drug development. CEO Jo Viney emphasized Tessier's role in building strategic partnerships and expanding the company’s promising pipeline.

Positive

• Appointment of a highly experienced CBO, Maude Tessier, expected to drive strategic growth.
• Tessier's track record includes securing a $1B+ strategic partnership at Ikena Oncology.
• Her previous experience includes significant roles that led to over $260M in capital acquisition.

Negative

• Concerns about continuity and experience gaps with leadership changes.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier brings over 16 years of company building experience with a multi-disciplinary background in business development, corporate strategy, corporate communications, IP management, and portfolio and program management in public and private biotechnology, pharmaceutical and academic organizations.

(Photo: Business Wire)

“We are very pleased to welcome Maude to the Seismic leadership team. Seismic is in a period of significant growth and Maude will play a vital role in implementing and executing our long-term business, partnering and financing strategy. Her proven track record of cultivating biopharma partnerships and strategic deals to advance new medicines will help drive the tremendous opportunities ahead of us at Seismic,” said Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic. “Maude’s versatile leadership experience across a range of company sizes, deep business acumen and collaborative team spirit are an ideal fit for our team as we chart the course for Seismic as the machine learning immunology company and build a pipeline of novel medicines for autoimmune diseases.”

“I couldn’t be more delighted to join the outstanding team at Seismic at this exciting time when the company is building momentum with its leading-edge platform and promising pipeline candidates,” said Dr. Tessier. “I look forward to working alongside Jo and my Seismic colleagues to drive business strategies and foster opportunities that will enable the company to achieve its goals as an immunology innovator that makes an impact on patients’ lives.”

Dr. Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where she built and managed the business development, legal and corporate strategy functions. At Ikena, she played a multi-faceted role leading key company building initiatives, including the negotiation and execution of a $1B+ strategic partnership with BMS, the strategy and execution of the company rebranding and pipeline expansion into targeted oncology, the acquisition of Amplify Medicines, and as part of the executive team, drove core elements of financing activities resulting in over $260M in private and public capital. Prior to Ikena, she was Executive Director, Business Development and Licensing at Merck & Co, leading oncology partnering in the Boston innovation hub. Dr. Tessier previously served as Assistant Director, Business Development and Strategic Initiatives at Boston Children’s Hospital. She began her career at Xanthus Pharmaceuticals, a venture-backed oncology biotech company in Cambridge, Mass., where she had key roles in business development and program management of a Phase 3 drug candidate leading to its eventual FDA approval. She holds a BSc in Biochemistry from McGill University and a PhD from the Department of Medical Biophysics at the University of Toronto.

About Seismic Therapeutic

Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005370/en/

Kathryn Morris, The Yates Network

914-204-6412

kathryn@theyatesnetwork.com

Source: Seismic Therapeutic, Inc.

FAQ

Who is Maude Tessier and what is her role at Seismic Therapeutic?

Maude Tessier is the newly appointed Chief Business Officer at Seismic Therapeutic, bringing over 16 years of experience in biotech and business development.

What previous experience does Maude Tessier have?

Before joining Seismic, Tessier served as CBO at Ikena Oncology, where she played a key role in major partnerships and capital acquisition.

How will Maude Tessier impact Seismic Therapeutic's business strategy?

Tessier is expected to implement and execute long-term business and financing strategies and enhance partnership opportunities.